Aclaris Therapeutics (ACRS) reported Q4 Revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 Revenue for the quarter came in at $9.21 million versus the consensus estimate of $2.08 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Canada's Competition Bureau moves to block B&G Foods' Green Giant sale
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance